

AMP 2018 Molecular Pathology Outreach Course

AMPIcons: A Practical Molecular Toolkit and Case Studies

Wednesday, October 31, 2018

Grand Hyatt Presidio ABC 3rd Floor, San Antonio, Texas

DETAILED AGENDA

TIME	SESSION	SPEAKER	CE Hours
7:30am	Registration and Continental Breakfast		
8:15am	Welcome and Introductions	Cecilia C. S. Yeung, MD <i>Fred Hutchinson Cancer Research Center</i>	NA
8:20am	HOT TOPICS in Molecular Diagnostics	Kojo S. J. Elenitoba-Johnson, MD <i>University of Pennsylvania, Perelman School of Medicine</i>	NA
9:05am	Molecular Testing Landscape – Pre-analytical Considerations <ul style="list-style-type: none"> Compare main types of samples submitted for molecular testing highlighting key criteria for specimen selection. Determine the rationale for specimen requirements for molecular testing. Assess requirements for the sample adequacy in relation to the test performance characteristics. 	Anna Yemelyanova, MD <i>University of Alabama at Birmingham</i>	0.5
9:40am	BREAK		

Lectures and Break-out Sessions			CE Hours
10:00am	Non-PCR based Methodologies and Clinical Applications <ul style="list-style-type: none"> Explain the mechanism of the cleavase probe signal amplification methodology. Describe the differences between signal amplification and target amplification and identify a clinical application of the methodology. 	Cynthia L. Jackson, PhD <i>Rhode Island Hospital and Brown University Alpert Medical School</i>	0.75
10:15am	Non-PCR Case Studies and Break-out Session <p><i>Hybridization based nucleic acid counting</i></p> <ul style="list-style-type: none"> Recognize the utility of molecular testing in breast cancer prognosis. Identify and appraise the characteristics of the NanoString Prosigna assay. Identify and select the appropriate tissue specimens for use with the Prosigna assay. <p><i>Fluorescence in situ hybridization (FISH) for the detection of structural and copy number variation</i></p> <ul style="list-style-type: none"> Explain common appropriate use of FISH in clinical diagnostics. Interpret common ISCN nomenclature for FISH results. Interpret common FISH images. 	Rashmi Goswami, MD PhD <i>University of Toronto</i> Kristy R. Crooks, PhD <i>University of Colorado, Denver</i>	
10:35am	Q&A Session		
10:40am	PCR Methodologies and Specialized PCR Applications <ul style="list-style-type: none"> Assess which method of detecting PCR amplification is most suitable for a given clinical assay. Describe clinical situations which call for a single amplicon versus multiplex PCR design. 	Jeffrey Gagan, MD PhD <i>UT Southwestern University</i>	0.75
10:55am	PCR Case Studies and Break-out Session <p><i>Nested Multiplex PCR for Multi-Pathogen Meningitis Detection</i></p> <ul style="list-style-type: none"> Describe the clinical utility of multiplex syndromic panels. Explain the advantages and limitations of the meningitis syndromic panel testing. <p><i>Specialized PCR Applications in Cystic Fibrosis</i></p> <ul style="list-style-type: none"> Describe the principles of Multiplex Ligation-dependent Probe Amplification (MLPA) for copy number detection. Evaluate Cystic Fibrosis carrier screening data and select cases where MLPA is an important adjunct to routine methods. 	Preeti Pancholi, PhD <i>Ohio State University</i> Mark D. Ewalt, MD <i>University of Colorado, Denver</i>	
11:15am	Q&A Session		

11:20am	Micro Array and Hybridization-based Technology and its Clinical Application <ul style="list-style-type: none"> Describe microarray technology. Apply microarray technology. 	Yasmine Akkari, PhD <i>Legacy Health</i>	0.75
11:35am	Array Case Studies and Break-out Session <p><i>Microarrays in Oncology: Case Studies</i></p> <ul style="list-style-type: none"> Apply microarray technology in oncology case studies. <p><i>Oligo Hybridization-based methodology: Microarray in the Infectious Diseases Diagnostic Laboratory</i></p> <ul style="list-style-type: none"> Explain how microarray technology is used in the Clinical Microbiology Laboratory. Discuss the impact of microarray technology on patient care. 	Yasmine Akkari, PhD Sophie S. Arbefeville, MD <i>University of Minnesota Medical Center</i>	
11:55am	Q&A Session		
12:00pm	LUNCH		NA

Lectures and Break-out Sessions			
1:15pm	Introduction to NGS Platform & Clinical Applications <ul style="list-style-type: none"> Describe the two main steps of a library preparation and some of the different variations that are possible. Compare different next-generation sequencing platforms and understand the basic chemical differences. Provide examples of clinical applications for NGS. 	Cecilia C. S. Yeung, MD	1.0
	Introduction to Bioinformatics Pipeline & Data Analysis <ul style="list-style-type: none"> Select the appropriate database to research a given genomic variant. Arrange the essential steps of a DNA next-generation sequencing bioinformatics pipeline. 	Joshua Coleman, MD <i>University of Utah</i>	
2:15pm	BREAK		NA
2:30pm	NGS Case Studies and Break-out Session <p><i>Using Next Generation Sequencing in Constitutional Genetics: Glycogen Storage Disease</i></p> <ul style="list-style-type: none"> Discuss indications, diagnosis, and typing of glycogen storage disease and the benefits of using next generation sequencing. Describe NGS sequencing and analysis in constitutional genetics using the Ion Torrent PGM. Discuss criteria for identification and reporting of variants found. <p><i>Solid Tumor NGS case study</i></p> <ul style="list-style-type: none"> Describe molecular alterations in GIST. Discuss limitations of NGS technology. <p><i>Next Generation Sequencing in Hematologic Malignancies</i></p> <ul style="list-style-type: none"> Describe a fusion gene and possible testing modalities to identification of gene fusion. Identify common and significant fusion genes common in myeloid neoplasms. <p><i>Whole Exome Sequencing and Complex Phenotypes</i></p> <ul style="list-style-type: none"> Show the importance of Whole Exome Sequencing (WES) for identification of known and new genes in families segregating with Mendelian diseases. Identify the appropriate applications to WES testing. Evaluate the usefulness and pitfalls of the technique for investigation of cases with mixed / complex phenotypes not described in the literature. 	Barbara Anderson, BS, MS <i>Duke Molecular Diagnostic Laboratory</i> Susan Hsiao, MD <i>Columbia University</i> Brittany Coffman, MD <i>University of New Mexico</i> Roberta Sitnik, MSc PhD <i>Hospital Israelita Albert Einstein</i>	1.0

3:30pm	Closing Remarks, Questions, and Evaluations	Cecilia C. S. Yeung, MD	NA
3:45pm	Adjourn		